This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

DosingDosingIBRANCE® Dosing
 
Monitoring Requirements
SafetySafetyIBRANCE® Safety ProfileNeutropeniaAdverse Event ManagementClinical Trials
Clinical TrialsIBRANCE® Clinical TrialsIBRANCE® PALOMA-2 Trial
 
IBRANCE® PALOMA-3 Trial
Real World EvidenceReal World EvidenceIBRANCE® Real World EvidenceIRIS (UK) StudyROIS
 
P-REALITY X
Patient ProfilesThe Ibrance® PatientPatient ProfilesAlison - >65 years with comorbiditiesBecky - Postmenopausal with bone-only diseaseSupport and ResourcesSupport and ResourcesIBRANCE Service SupportMaterials
 
Videos

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here.  Adverse event reporting information can be found at the bottom of the page.

Confidence Built on Evidence1-31

IBRANCE® (palbociclib) is indicated for the treatment of HR+ HER2- locally advanced or metastatic breast cancer in combination with an AI, or in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.1 

Dosing

Dosing and monitoring requirements for IBRANCE®

More information

Loading
Clinical Trials

IBRANCE® PALOMA-2 and PALOMA-3 Clinical Trial Results, including efficacy and safety outcomes

Learn More Loading
Safety

Important safety information and safety outcomes from IBRANCE® PALOMA Clinical Trials

See Results Loading
Real World Evidence

Real-world evidence for IBRANCE® (palbociclib) in HR+ HER2- advanced Breast Cancer

View Loading
Service Support
  • Non-Medical Prescribing (NMP) Service Implementation
  • Electronic Patient-Reported Outcome Measures (ePROMs) Implementation
  • Future Proofing Cancer Services - National Case Studies
  • IBRANCE® Dispense and Delivery Service
View Resources Loading

AI : Aromatase Inhibitor,  ET : Endocrine Therapy,  HR+/HER2– : Hormone Receptor Positive / Human Epidermal Growth Factor Receptor 2 Negative,  LHRH : Luteinizing Hormone-Releasing Hormone,  mBC : metastatic Breast Cancer

References

IBRANCE® Summary of Product Characteristics for Great Britain click here. IBRANCE® Summary of Product Characteristics for Northern Ireland click here.Finn RS, et al. N Engl J Med 2016;375:1925–1936.Rugo HS, et al. Breast Cancer Res Treat 2019;174:719–729.Cristofanilli M, et al. Lancet Oncol 2016;17:425–439.Turner NC, et al. N Engl J Med 2018;379:1926–1936.Mycock K, et al. Poster P510. Presented at the European Breast Cancer Conference, 2–3 October 2020, virtual.Ettl J, et al. Breast Cancer Res 2020;22:27.Taylor-Stokes G, et al. Poster 269P. Presented at the European Society for Medical Oncology Congress, 19–21 September 2020, virtual.Pfizer Ltd. Data on file. IBRANCE Real-World Insights (IRIS) UK results, 2020. REF-PLB0472;Taylor-Stokes G, et al. Breast 2019;43:22–27.Waller J, et al. J Glob Oncol 2019;5:JGO1800239.Mycock K, et al. Curr Oncol 2021;28:678–688Mycock K, et al. Future Oncol 2022;18:349–362Kish JK, et al. Breast Cancer Res 2018;20:37.Mycock K, et al. Clin Ther 2022;44:1588-1601.Richardson D, et al. Breast Cancer Res Treat 2021;187:113–124.De Laurentiis M, et al. Poster P3-11-25. Presented at San Antonio Breast Cancer Symposium, 14–10 December 2019, San Antonio, TX, USA.Caillet P, et al. Presentation 1012. Presented at ASCO, 4–8 June 2021, Virtual.NCT03280303. Available at: https://clinicaltrials.gov/ct2/show/NCT03280303 (accessed September 2023).Rugo HS, et al. NPJ Breast Cancer 2022;8:114.Goyal RK, et al. Cancer 2023;129:1051–1063.Darden C, et al. Future Oncol 2019;15:141–150.El Badri S, et al. Breast 2021;60:199–205.Trocio J, et al. Poster P6-18-29. Presented at San Antonio Breast Cancer Symposium, 4–8 December 2018, San Antonio, TX, USA.Karuturi MS, et al. Poster PS7-19. Presented at the San Antonio Breast Cancer Symposium, 8–12 December 2020, virtual.Harbeck N, et al. Abstract 165P. Presented at ESMO, 2–4 May 2019, Berlin, Germany.Karuturi MS, et al. Poster P1-18-25. Presented at San Antonio Breast Cancer Symposium, 7–10 December 2021, San Antonio, TX, USA.Guarin A, et al. Poster 004. Presented at MBCC Conference, 7–8 August 2020, virtual symposium.Palumbo R, et al. Ther Adv Med Oncol 2021;13:1–18.

Palmieri C, et al. Br J Cancer 2023;129:852–860.

Finn RS, et al. Presentation LBA1003. Presented at ASCO, 3-7 June 2022, Chicago, IL, USA

PP-IBR-GBR-5395. October 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​